Evidence map›Paper›PMID 40201539›Full record

ArticleJAC-antimicrobial resistance2025

Alba Muñoz-Santa, Carla López-Causapé, Alba Bellés, Xavier Gómez-Arbonés, Sara Cortés-Lara, Mercè García-González, Ricardo Pifarré-Teixidó, Antonio Oliver

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alba Muñoz-SantaServicio de Análisis Clínicos, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biomèdica de Lleida (IRB Lleida), Universitat de Lleida, Lleida, Spain.
Carla López-CausapéServicio de Microbiología, Hospital Univeristario Son Espases, Instituto de Investigación Sanitaria Illes Balears, CIBERINFEC, Palma de Mallorca, Spain.ORCID https://orcid.org/0000-0003-2228-2005
Alba BellésServicio de Análisis Clínicos, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biomèdica de Lleida (IRB Lleida), Universitat de Lleida, Lleida, Spain.
Xavier Gómez-ArbonésDepartamento de Medicina y Cirugía, Institut de Recerca Biomèdica de Lleida (IRB Lleida), Universitat de Lleida, Lleida, Spain.
Sara Cortés-LaraServicio de Microbiología, Hospital Univeristario Son Espases, Instituto de Investigación Sanitaria Illes Balears, CIBERINFEC, Palma de Mallorca, Spain.
Mercè García-GonzálezServicio de Análisis Clínicos, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biomèdica de Lleida (IRB Lleida), Universitat de Lleida, Lleida, Spain.
Ricardo Pifarré-TeixidóServicio de Neumología, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain.
Antonio OliverServicio de Microbiología, Hospital Univeristario Son Espases, Instituto de Investigación Sanitaria Illes Balears, CIBERINFEC, Palma de Mallorca, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Methods: We determined the antibiotic susceptibility profiles of a collection of 100 Results: Twelve isolates were classified as MDR (12%) and six were found to be carbapenemase (VIM-2) producers (6%). Of note, two of the VIM-2-producing isolates were carbapenem susceptible due to the presence of inactivating mutations in MexAB-OprM efflux pump components. These isolates exhibited properties of chronic Conclusions: Altogether, these findings suggest that

Identifiers

PMID40201539
PMCPMC11976719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.